Share on StockTwits

CorMedix (NASDAQ:CRMD) CEO Randy Milby bought 3,125 shares of the company’s stock in a transaction that occurred on Friday, August 29th. The stock was purchased at an average cost of $2.00 per share, for a total transaction of $6,250.00. Following the completion of the transaction, the chief executive officer now directly owns 15,247 shares in the company, valued at approximately $30,494. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of analysts have recently weighed in on CRMD shares. Analysts at Zacks downgraded shares of CorMedix to a “neutral” rating in a research note on Monday, July 28th. They now have a $2.20 price target on the stock. Analysts at Roth Capital initiated coverage on shares of CorMedix in a research note on Thursday, July 24th. They set a “buy” rating and a $3.00 price target on the stock.

CorMedix (NASDAQ:CRMD) traded down 2.00% on Thursday, hitting $1.862. 3,400 shares of the company’s stock traded hands. CorMedix has a 52 week low of $0.66 and a 52 week high of $3.20. The stock’s 50-day moving average is $1.95 and its 200-day moving average is $1.96. The company’s market cap is $40.7 million.

CorMedix (NASDAQ:CRMD) last issued its quarterly earnings data on Wednesday, August 20th. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.13) by $0.13. On average, analysts predict that CorMedix will post $-0.61 earnings per share for the current fiscal year.

CorMedix Inc (NASDAQ:CRMD) is a biopharmaceutical company that focuses on in-licensing, developing and commercializing therapeutic products for the treatment of cardiac and renal dysfunction, also know as Cardiorenal disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.